drugset / Trial / NCT01432405

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

NCT01432405

Phase 4 Completed 24 enrolled Baylor College of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the effect of exenatide, an anti-diabetes medication, on liver fat and blood levels of proteins that influence liver fat.

Timeline

Start
2007-06
Primary completion
2008-07
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug Subcutaneous
Subject Pioglitazone Small molecule 45 mg Oral